Blueprint Medicines (BPMC) Misses Q3 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Blueprint Medicines (BPMC) Misses Q3 EPS by 15c

Blueprint Medicines Reports Third Quarter 2018 Financial Results

October 30, 2018 7:00 AM EDT

CAMBRIDGE, Mass., Oct. 30, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2018.

"Our third quarter and recent accomplishments represent tremendous progress across our portfolio, marked by the receipt of positive regulatory... More